Carmat - A 3months relief
Carmat raised EUR 16.5m via a public offering. The overallotment option was partially exercised for a gross amount of EUR 1.5m. 4.1m shares will be issued, resulting in 17% dilution. Cash runway is extended by 3 months. The success of this offering is reassuring as Carmat had runway until end of this month. Nevertheless, this is only a short-term relief (3 months) as the company still needs between EUR 35-50m – depending on the outcome of the discussions with the EIB – to bridge the gap until next year. We have included this capital increase and the related dilution inCarmat is focused on the research and development of an innovative product in the medical sector, developing an orthotopic and biocompatible artificial heart which is completely implantable, as well as its electrical power supply system and remote diagnosis system. Co. is developing a long-term therapeutic solution for patients who suffer from advanced bi-ventricular heart failure and who are not eligible for cardiac transplantation and who have exhausted all drug possibilties. Co. is still in the phase of research and development and thus do not generate any revenues.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.